Schnieders Capital Management LLC Acquires 6,584 Shares of Johnson & Johnson $JNJ

Key Points

• Schnieders Capital Management LLC increased its stake in Johnson & Johnson by 9.8%, acquiring 6,584 additional shares, bringing its total holdings to 73,680 shares valued at approximately $11.25 million.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, with an ex-dividend date of November 25th, yielding around 2.7% annually.
• Multiple analysts have upgraded their ratings for Johnson & Johnson, with UBS raising its target price from $190 to $214 and Goldman Sachs from $186 to $212, reflecting strong confidence in the stock's potential.

Schnieders Capital Management LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 9.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 73,680 shares of the company's stock after acquiring an additional 6,584 shares during the period. Johnson & Johnson comprises approximately 2.0% of Schnieders Capital Management LLC's portfolio, making the stock its 13th biggest holding. Schnieders Capital Management LLC's holdings in Johnson & Johnson were worth $11,255,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Ellis Investment Partners LLC grew its position in Johnson & Johnson by 0.7% during the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company's stock valued at $1,307,000 after acquiring an additional 62 shares during the last quarter. Cypress Wealth Services LLC grew its holdings in shares of Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company's stock worth $1,013,000 after purchasing an additional 62 shares during the last quarter. Horizon Bancorp Inc. IN grew its holdings in shares of Johnson & Johnson by 11.2% in the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company's stock worth $97,000 after purchasing an additional 64 shares during the last quarter. Global Strategic Investment Solutions LLC grew its holdings in shares of Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company's stock worth $294,000 after purchasing an additional 65 shares during the last quarter. Finally, JSF Financial LLC grew its holdings in shares of Johnson & Johnson by 2.2% in the second quarter. JSF Financial LLC now owns 2,993 shares of the company's stock worth $457,000 after purchasing an additional 65 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $191.93 on Wednesday. The stock has a fifty day moving average of $181.27 and a 200 day moving average of $165.37. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48. The firm has a market capitalization of $462.23 billion, a price-to-earnings ratio of 18.53, a PEG ratio of 2.28 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is currently 50.19%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on JNJ shares. Cowen restated a "buy" rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. UBS Group raised their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a "buy" rating in a report on Tuesday, October 14th. The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a "buy" rating in a report on Thursday, October 9th. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Finally, Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $200.06.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.